Methods for reducing cattle reproductive diseases
View Patent ↗The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo - prajitno, Leptospira icterohaemorrhagia, Leptospira hardjo - bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.
1. A method of reducing abortions in pregnant animals, wherein said animals are cows or heifers which have been vaccinated prior to pregnancy with a therapeutically effective amount of a first vaccine composition comprising an attenuated Bovine Herpes Virus (BHV-1), said method comprising administering to the pregnant animals a therapeutically effective amount of a second vaccine composition comprising an attenuated live Bovine Herpes Virus (BHV-1).
2. A method of reducing abortions in pregnant animals, wherein said animals are cows or heifers which have been vaccinated prior to pregnancy with a therapeutically effective amount of a first vaccine composition comprising an attenuated Bovine Herpes Virus (BHV-1), said method comprising administering to the pregnant animals a therapeutically effective amount of a second vaccine composition comprising an attenuated live Bovine Herpes Virus (BHV-1) and at least one antigen selected from the group consisting of: Bovine Viral Diarrhea Virus (BVDV); an alt enuated live Parainfluenza Virus Type 3 (PLV3); an attenuated Bovine Respiratory Syncytial Virus (BRSV); Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo-bovis, Leptospira bratislava, and Campylobacter fetus.
3. The method of claim 1 or 2 , wherein said second vaccine composition further comprises an adjuvant.
4. The method of claim 1 or 2 , wherein said second vaccine composition is administered intramuscularly.
5. The method of claim 1 or 2 , wherein said second vaccine composition is administered subcutaneously.
6. The method of claim 1 or 2 , wherein said second vaccine composition contains from about 10 2 to about 10 10 TCID 50 units per dose of each virus.
7. The method of claim 1 or 2 , wherein the amount of said second vaccine composition administered is from about 0.1 to about 5.0 ml per dose.
8. The method of claim 1 or 2 , wherein the amount of said second vaccine composition administered is about 5 ml per dose.
9. The method of claim 1 or 2 , wherein the amount of said second vaccine composition administered is about 2 ml per dose.